Clinical Trials Browser

Recruiting × Cholangiocarcinoma × pembrolizumab × Clear all

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT06270706 2026-04-20

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05967182 2026-04-16

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Phase 2 Recruiting

24 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT06282575 2026-03-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Phase 3 Recruiting

286 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Recruiting

100 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT05429697 2022-09-27

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

Phase 2/3 Recruiting

128 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

Clinical Trials

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer